RFRieke Fischer

Rieke Fischer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rieke Fischer has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses

    by Lea Ruge, Felix John, Malte Verheyen, Richard Riedel, Sebastian Michels, Lucia Nogova, Heather Scharpenseel, Rieke Fischer, Sofia Stilianakis, Janna Siemanowski-Hrach, et al.

    Purpose:KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for approximately 1% to 7% of all KRAS mutations in non–small cell lung cancer (NSCLC). So far, the prognostic value of this cohort and its response to different treatment regimens remain unclear. Experimental Design:Between 2011 and 2023, diagnostic samples from patients with NSCLC were analyzed using next-generation sequencing. Molecular data were correlated with clinical records, and time-to-event analyses were performed using the Kaplan–Meier estimate. Results:Of the 8,862 analyzed probes, we identified 487 (5.5%) patients with KRAS Q61 mutations and further analyzed 365 patients. Most presented with Q61H (74.0%) and Q61L (20.8%) mutations that demonstrated distinct patterns in smoking history (7% vs. 3.3% never smokers, respectively) and co-mutational landscape. The most frequent co-mutations in Q61H were STK11 (45.8%), TP53 (32.1%), and KEAP1 (31.3%), whereas Q61L was mutually exclusive to STK11 and had a lower incidence of co-occurring KEAP1 mutations (11.5%). The median overall survival for the entire cohort was 12.3 months, with a favorable survival of 22.1 and 65.4 months for patients receiving combined chemoimmunotherapy and immunotherapy as first-line treatment, respectively. Real-world progression-free survival was significantly prolonged in patients receiving immunotherapy, either as monotherapy or combined therapy, versus chemotherapy (CTX) in the first-line setting (P < 0.01). Conclusions:KRAS Q61H and Q61L were the predominant mutational subtypes and demonstrated distinct molecular and clinical characteristics, with differences in the co-mutational landscape contributing to the observed survival differences between subtypes. Immunotherapy-based regimens were associated with more favorable outcomes compared with CTX, particularly in patients with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%), underscoring the importance of subtype-specific molecular characterization in clinical decision-making.See related commentary by Meazza Prina and Mezquita, p. 5014

  • Open Access

    Supplementary Data 1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses

    by Lea Ruge, Felix John, Malte Verheyen, Richard Riedel, Sebastian Michels, Lucia Nogova, Heather Scharpenseel, Rieke Fischer, Sofia Stilianakis, Janna Siemanowski-Hrach, et al.

    Supplementary Figures and Tables

  • FIND: A Phase II Study to Evaluate the Efficacy and Safety of Erdafitinib in FGFR -Altered NSCLC

    by Lucia Nogova, Florian Malchers, Axel M. Hillmer, Inken Terjung, Heather Scharpenseel, Anna Rasokat, Sabine Merkelbach-Bruse, Andreas H. Calaminus, Janna Siemanowski-Hrach, Matthias Scheffler, et al.

    Purpose: FGFR alterations occur in approximately 2% of patients with non–small cell lung cancer (NSCLC), predominantly in squamous cell histology (sqNSCLC). We evaluated the efficacy of the selective FGFR1–4 inhibitor erdafitinib in patients with FGFR-altered NSCLC. Patients and Methods: Patients with NSCLC were prescreened within the national Network Genomic Medicine (nNGM) for FGFR mutations/fusions. Patients were treated with erdafitinib after assessment of every alteration in the study-specific molecular board in three cohorts: (i) high-confidence activating FGFR fusions, (ii) high-confidence activating FGFR mutations, and (iii) low-confidence activating FGFR alterations. The primary objective was the best confirmed overall response rate on erdafitinib in cohorts 1 and 2 assessed by RECIST 1.1 every 8 weeks. Statistical analysis was based on the Simon two-stage minimax design. Results: Between July 2019 and September 2022, 44,537 patients were prescreened in nNGM, 26 patients were enrolled in stage I of the Simon design, and 4 patients failed screening. Most patients were male (77%) and had sqNSCLC (73%). All patients were current or previous smokers. Of 22 patients on erdafitinib, 7 were treated in cohort 1, 8 were treated in cohort 2, and 7 were treated in cohort 3. In cohort 1, 2 of 7 patients achieved partial response (PR). However, one PR remained unconfirmed. The best response in cohort 2 was stable disease. The most observed adverse events of any grade were hyperphosphatemia (in 45.5%) and diarrhea and dry mouth (both in 31.8% of patients). Conclusions: According to the first stage of the two-stage Simon design, erdafitinib showed preliminary efficacy in NSCLC with FGFR fusions. Further molecular and clinical data are needed to evaluate the efficacy of FGFR inhibition in NSCLC, especially in patients with FGFR mutations.

  • Open Access

    Data from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

    by Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel, Sebastian Yves Friedrich Michels, Richard Riedel, Rieke Fischer, Carolin Jakob, Janna Siemanowski-Hrach, Jana Fassunke, et al.

    Purpose:KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood.Experimental Design:In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed.Results:The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months.Conclusions:KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.

  • Open Access

    Supplementary Data 1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

    by Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel, Sebastian Yves Friedrich Michels, Richard Riedel, Rieke Fischer, Carolin Jakob, Janna Siemanowski-Hrach, Jana Fassunke, et al.

  • Open Access

    Supplementary Figure S2 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

    by Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel, Sebastian Yves Friedrich Michels, Richard Riedel, Rieke Fischer, Carolin Jakob, Janna Siemanowski-Hrach, Jana Fassunke, et al.

    Supplementary Figure S2: Kaplan-Meier statistics on median real-world overall survival (rwOS) in different subgroups

  • Open Access

    Supplementary Figure S3 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

    by Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel, Sebastian Yves Friedrich Michels, Richard Riedel, Rieke Fischer, Carolin Jakob, Janna Siemanowski-Hrach, Jana Fassunke, et al.

    Supplementary Figure S3: In support of Fig. 5: PD-L1 expression in the different therapy subgroups

  • Open Access

    Supplementary Figure S1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

    by Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel, Sebastian Yves Friedrich Michels, Richard Riedel, Rieke Fischer, Carolin Jakob, Janna Siemanowski-Hrach, Jana Fassunke, et al.

    Supplementary Figure S1: Localization of genetic co-alterations (Created with cBioPortal [Scheffler M][https://www.cbioportal.org])

  • Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses

    by Lea Ruge, Felix John, Malte Verheyen, Richard Riedel, Sebastian Michels, Lucia Nogova, Heather Scharpenseel, Rieke Fischer, Sofia Stilianakis, Janna Siemanowski-Hrach, et al.

    Purpose: KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for approximately 1% to 7% of all KRAS mutations in non–small cell lung cancer (NSCLC). So far, the prognostic value of this cohort and its response to different treatment regimens remain unclear. Experimental Design: Between 2011 and 2023, diagnostic samples from patients with NSCLC were analyzed using next-generation sequencing. Molecular data were correlated with clinical records, and time-to-event analyses were performed using the Kaplan–Meier estimate. Results: Of the 8,862 analyzed probes, we identified 487 (5.5%) patients with KRAS Q61 mutations and further analyzed 365 patients. Most presented with Q61H (74.0%) and Q61L (20.8%) mutations that demonstrated distinct patterns in smoking history (7% vs. 3.3% never smokers, respectively) and co-mutational landscape. The most frequent co-mutations in Q61H were STK11 (45.8%), TP53 (32.1%), and KEAP1 (31.3%), whereas Q61L was mutually exclusive to STK11 and had a lower incidence of co-occurring KEAP1 mutations (11.5%). The median overall survival for the entire cohort was 12.3 months, with a favorable survival of 22.1 and 65.4 months for patients receiving combined chemoimmunotherapy and immunotherapy as first-line treatment, respectively. Real-world progression-free survival was significantly prolonged in patients receiving immunotherapy, either as monotherapy or combined therapy, versus chemotherapy (CTX) in the first-line setting (P < 0.01). Conclusions: KRAS Q61H and Q61L were the predominant mutational subtypes and demonstrated distinct molecular and clinical characteristics, with differences in the co-mutational landscape contributing to the observed survival differences between subtypes. Immunotherapy-based regimens were associated with more favorable outcomes compared with CTX, particularly in patients with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%), underscoring the importance of subtype-specific molecular characterization in clinical decision-making. See related commentary by Meazza Prina and Mezquita, p. 5014


  • Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

    by Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel, Sebastian Yves Friedrich Michels, Richard Riedel, Rieke Fischer, Carolin Jakob, Janna Siemanowski-Hrach, Jana Fassunke, et al.

    Purpose: KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood. Experimental Design: In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed. Results: The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months. Conclusions: KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.